Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
GROW Funds Mike Collins, Matt Clarke, Chase McIntosh, Carl Wiese | “Axsome Therapeutics Inc. (AXSM) was a new addition to investor portfolios in January of 2025 and has been a positive contributor since. Axsome is a biopharmaceutical company focused on central nervous system conditions such as Alzheimer's Disease Agitation, Major Depressive Disorder, Migraines, and Fibromyalgia. Their products target serious conditions impacting over 150 million people in the United States. Axsome has four products commercially available today with two others in late stages of approval, representing over $16 billion in potential peak sales versus $630 million of revenue in 2025. Auvelity, approved in August 2022 for major depressive disorder, exceeded $500 million in sales in 2025. During Q4 2025, Axsome filed for a label expansion for Alzheimer's Disease Agitation and received accelerated FDA review. We believe Auvelity alone could reach $2 billion in peak sales for this indication, with approval expected by mid-year, and view the company as a potential acquisition target. BSD Analysis: Axsome is a commercial-stage biopharma with approved CNS drugs and a pipeline targeting high-unmet-need indications. Revenue growth is accelerating as new launches gain traction. The market opportunity in depression, migraine, and sleep disorders is massive. Execution risk exists around commercialization spend and reimbursement. Unlike many biotechs, Axsome has real products on the shelf. Pipeline readouts add optionality beyond current revenues. This is a growth biotech transitioning from story to substance.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
